Rollins Financial Advisors LLC Sells 505 Shares of Eli Lilly and Company $LLY

Rollins Financial Advisors LLC trimmed its position in shares of Eli Lilly and Company (NYSE:LLY) by 27.6% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,328 shares of the company’s stock after selling 505 shares during the period. Rollins Financial Advisors LLC’s holdings in Eli Lilly and Company were worth $1,014,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Prestige Wealth Management Group LLC lifted its holdings in shares of Eli Lilly and Company by 1.2% during the 3rd quarter. Prestige Wealth Management Group LLC now owns 2,068 shares of the company’s stock worth $1,578,000 after acquiring an additional 25 shares during the period. Tableaux LLC acquired a new position in Eli Lilly and Company during the third quarter valued at approximately $697,000. Cozad Asset Management Inc. lifted its stake in Eli Lilly and Company by 3.5% during the third quarter. Cozad Asset Management Inc. now owns 22,457 shares of the company’s stock worth $17,135,000 after purchasing an additional 762 shares during the last quarter. Colonial Trust Co SC boosted its holdings in shares of Eli Lilly and Company by 0.5% in the 3rd quarter. Colonial Trust Co SC now owns 17,604 shares of the company’s stock valued at $13,432,000 after purchasing an additional 94 shares in the last quarter. Finally, Palumbo Wealth Management LLC increased its stake in shares of Eli Lilly and Company by 4.2% in the 3rd quarter. Palumbo Wealth Management LLC now owns 1,035 shares of the company’s stock valued at $790,000 after purchasing an additional 42 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Head‑to‑head trial news showing Novo’s next‑gen obesity candidate underperformed Lilly’s tirzepatide has strengthened expectations that Lilly will retain market share in the high-growth weight‑loss category; that data triggered earlier upside in LLY. Trial Readout Lifts Lilly
• Positive Sentiment: Lilly launched an FDA‑cleared multi‑dose KwikPen for Zepbound (tirzepatide), giving patients a more convenient monthly device at the same self‑pay price — a commercial move intended to improve adherence and retention. Zepbound KwikPen Launch
• Positive Sentiment: Wall Street remains constructive on LLY’s longer‑term outlook (Goldman and other analysts keep Buy/Outperform calls and elevated price targets), supporting the stock’s valuation against the sector noise. Analyst Support
• Neutral Sentiment: Early clinical work showing benefit of combining Zepbound with other therapies (e.g., Taltz) and investor commentary on retention strategies (multi‑dose pen) add incremental optionality but are not immediate revenue drivers. Pipeline/Combo Data
• Negative Sentiment: Nuevo pricing shock — Novo Nordisk announced U.S. list price cuts of up to ~50% for Ozempic/Wegovy (to ~$675/month starting 2027). That move has rattled the sector, and LLY shares have slipped as investors reassess pricing dynamics and potential margin/market‑share impacts across GLP‑1s. Novo Price Cut Hits Stocks
• Negative Sentiment: Broader competition and pricing pressure could compress realized prices or accelerate payer negotiations over time, a structural risk to growth if competitors follow price cuts or insurers demand steeper discounts. Price Competition Risk

Eli Lilly and Company Stock Down 1.5%

Shares of NYSE LLY opened at $1,042.68 on Wednesday. The company has a 50 day simple moving average of $1,054.49 and a 200 day simple moving average of $923.72. The firm has a market cap of $983.62 billion, a PE ratio of 45.43, a price-to-earnings-growth ratio of 1.23 and a beta of 0.39. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. The firm had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company’s revenue for the quarter was up 42.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 30.15%.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on LLY shares. Bank of America dropped their price objective on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a research report on Monday, December 15th. Rothschild & Co Redburn increased their target price on shares of Eli Lilly and Company from $775.00 to $830.00 and gave the stock a “neutral” rating in a report on Monday, January 26th. Wells Fargo & Company raised their price target on shares of Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Eli Lilly and Company in a report on Monday, December 22nd. Finally, Leerink Partners increased their price objective on shares of Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the company an “outperform” rating in a research note on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $1,229.33.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.